Analyst Rating Update on Abbott Laboratories (ABT)

Abbott Laboratories (ABT) has an average broker rating of 1.6, which is interpreted as a Buy, as rated by 15 equity analysts. Nonetheless, 10 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 4 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Abbott Laboratories (ABT) : The most positive equity analysts on Abbott Laboratories (ABT) expects the shares to touch $50, whereas, the least positive believes that the stock will trade at $45 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $48.55 with an expected fluctuation of $1.44 from the mean.

For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Jefferies maintains its ratings on Abbott Laboratories (NYSE:ABT). In the latest research report, Jefferies raises the target price from $45 per share to $49 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on July 14, 2016.


Abbott Laboratories (NYSE:ABT): The stock opened at $45.07 on Wednesday but the bulls could not build on the opening and the stock topped out at $45.09 for the day. The stock traded down to $44.83 during the day, due to lack of any buying support eventually closed down at $44.95 with a loss of -0.27% for the day. The stock had closed at $45.07 on the previous day. The total traded volume was 7,783,077 shares.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.